NCI Trial of Dual Immunotherapy Bintrafusp Alfa for Bladder Cancer Terminated Early
A Phase II NCI trial testing bintrafusp alfa in metastatic urothelial carcinoma was terminated after enrolling only 2 patients.
Summary
This Phase II clinical trial, sponsored by the National Cancer Institute, tested bintrafusp alfa (M7824) — a novel bifunctional immunotherapy — in patients with metastatic urothelial carcinoma who had already received chemotherapy or immunotherapy. Bintrafusp alfa is designed to simultaneously block two immune-suppressive pathways used by cancer cells: the PD-L1 checkpoint and TGF-beta signaling. The trial enrolled both checkpoint inhibitor-naive and checkpoint inhibitor-refractory patients and planned to administer the drug via IV infusion every two weeks in 28-day cycles. However, the study was terminated early after enrolling just 2 of its intended participants, and it ran for less than one year. As a result, no efficacy or safety conclusions can be drawn from this trial regarding the drug's potential in bladder cancer treatment.
Detailed Summary
Metastatic urothelial carcinoma — a cancer arising from the bladder and urinary tract lining — carries a poor prognosis, with limited treatment options and modest response rates even to modern immunotherapies. New therapeutic strategies, particularly those targeting multiple immune evasion pathways simultaneously, represent a critical unmet need for patients who have progressed beyond standard care.
This Phase II trial, conducted through the National Cancer Institute, investigated bintrafusp alfa (M7824), a first-in-class bifunctional fusion protein. The drug is uniquely designed to block two distinct immune-suppressive mechanisms simultaneously: the PD-L1 checkpoint pathway and TGF-beta signaling — both of which cancer cells exploit to evade immune destruction. The study enrolled adults aged 18 and older with metastatic urothelial carcinoma who had previously received chemotherapy or immunotherapy, covering both checkpoint inhibitor-naive and refractory populations. Participants received IV infusions of bintrafusp alfa every two weeks in 28-day cycles.
Unfortunately, the trial was terminated after enrolling only 2 patients, and it concluded approximately one year after its start date in October 2021. No efficacy data or safety outcomes were reported in the available abstract, making it impossible to evaluate whether bintrafusp alfa demonstrated meaningful antitumor activity in this population.
The premature termination is clinically significant context. Across multiple oncology indications, bintrafusp alfa faced a series of trial failures and program discontinuations, which likely contributed to the early closure of this study. The bifunctional TGF-beta/PD-L1 blockade concept remains scientifically compelling, but clinical execution has proven difficult.
For clinicians and researchers in the urothelial cancer space, this trial underscores the ongoing challenge of translating mechanistically rational immunotherapy combinations into clinical success. Patients refractory to checkpoint inhibitors continue to represent a population with urgent need for novel interventions, and future trials should account for lessons learned from bintrafusp alfa's broader development history.
Key Findings
- Trial was terminated after enrolling only 2 of its intended patients, yielding no interpretable efficacy data.
- Bintrafusp alfa targets both PD-L1 and TGF-beta simultaneously, a mechanistically novel dual immunotherapy approach.
- The study included both checkpoint inhibitor-naive and refractory metastatic urothelial carcinoma patients.
- Treatment was administered as IV infusion every 2 weeks in 28-day cycles until progression or intolerance.
- Early termination reflects broader clinical failures of bintrafusp alfa across multiple cancer indications.
Methodology
This was a Phase II, single-arm, open-label study sponsored by the NCI, designed to evaluate bintrafusp alfa monotherapy in metastatic urothelial carcinoma across two cohorts: checkpoint inhibitor-naive and refractory patients. The drug was administered intravenously every 14 days. The trial was terminated after only 2 patients were enrolled, and no outcome data are available from this abstract.
Study Limitations
The summary is based on the abstract only, and no efficacy, response rate, or safety data are available due to the trial's early termination with only 2 enrolled patients. With such minimal enrollment, no conclusions about the drug's activity or tolerability in urothelial carcinoma can be drawn. The reasons for termination are not explicitly stated in the available record, limiting interpretation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.